Crestor still challenges Lipitor

The growing patient population and the increasing demand for cholesterol reducing "statins," has successfully sustained the appeal of this maturing market over the past several years. The marketing excellence, and the much-needed aggression demonstrated by Lipitor has transformed the way hyperlipidemia is treated today.

AstraZeneca’s key cholesterol drug Crestor failed to beat Pfizer Inc’s L...